Quantcast

Latest Cyclopropanes Stories

2014-09-29 08:31:11

This innovative combination of drugs could become the treatment of choice in those cases BARCELONA, Spain, September 29, 2014 /PRNewswire/ -- Laboratorios SALVAT S.A. announced today the top-line results from two Phase III studies comparing Ciprofloxacin 0.3% plus Fluocinolone Acetonide 0.025% Otic Solution to the components alone (Ciprofloxacin 0.3% otic solution and Fluocinolone Acetonide 0.025% otic solution) in the treatment of pediatric patients with Acute Otitis Media...

2014-09-07 08:20:19

DALLAS, September 7, 2014 /PRNewswire/ -- MarketOptimizer.org adds "Acute Coronary Syndrome - US Drug Forecast and Market Analysis to 2023", a new research report to its store. Overview of ACS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. The Acute Coronary Syndrome - US Drug Forecast and Market Analysis to 2023 report estimates that the total market size for the 7MM in...

2014-09-03 23:09:16

LifeScienceIndustryResearch.com adds Latest Report on “Market Research Report on Global and Chinese Ciprofloxacin HCl Industry, 2009-2019” to its store. Inquire Before Buying on this report at http://www.lifescienceindustryresearch.com/inquire-before-buying?rname=9568 Dallas, TX (PRWEB) September 03, 2014 Market Research Report on Global and Chinese Ciprofloxacin HCl Industry, 2009-2019 is a professional and in-depth market survey on Global and Chinese Ciprofloxacin HCl industry. The...

2014-08-25 08:28:30

Multimedia assets associated with the below announcement are now available. Assets include: b-roll footage, corporate sound bites, product images and additional information. Please click: http://www.multivu.com/players/English/7197331-viiv-healthcare-vhc-triumeq-fda-approval LONDON, Aug. 25, 2014 /PRNewswire/ -- On August 22, ViiV Healthcare announced that the US Food and Drug Administration (FDA) approved Triumeq(®) (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the...

2014-08-22 16:23:16

LONDON, Aug. 22, 2014 /PRNewswire/ -- ViiV Healthcare announced today that the US Food and Drug Administration (FDA) has approved Triumeq(®) (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection.(1) Triumeq is ViiV Healthcare's first dolutegravir-based fixed-dose combination, offering many people living with HIV the option of a single-pill regimen that combines the integrase strand transfer inhibitor (INSTI) dolutegravir, with the nucleoside...

2014-08-06 23:11:18

The DrugNews Center is the web’s largest source for prescription drug warnings, research and legal news. Visit http://www.DrugNews.net today. New York, NY (PRWEB) August 06, 2014 The birth control resource center at DrugNews.net is alerting women who have taken the oral contraceptives Yaz or Yasmin of new information on the site. A recent report shows the maker of the drugs has settled approximately 8,900 cases alleging they caused side effects*. DrugNews is a free online resource...

2014-07-31 16:27:33

OTTAWA, July 31, 2014 /CNW/ - Health Canada today released the July 2014 issue of the Canadian Adverse Reaction Newsletter (CARN). This issue includes an article on the anti-cancer drug cisplatin and the risk of blockage of the aorta, the body's main artery. It also includes an article on hydroxychloroquine, a drug used for rheumatoid arthritis, lupus, and malaria, and the risk of developing low blood sugar; and a case presentation on a suspected interaction between efavirenz, an...

2014-07-23 23:13:00

The DrugNews Center is the web’s largest source for prescription drug warnings, research and legal news. Visit http://www.DrugNews.net today. Chicago, IL (PRWEB) July 23, 2014 The birth control resource center at DrugNews.net is alerting women who have taken the oral contraceptives Yaz or Yasmin of new information on the site. A federal panel recently released updated records showing more than 8,500 cases still pending alleging side effects from the drugs*. DrugNews is a free online...

2014-07-17 16:26:09

NEW YORK, July 17, 2014 /PRNewswire/ -- Exelixis, Inc. (Nasdaq: EXEL) is a development stage biotech company. EXEL developed two cancer treatments cabozantinib (Cabo, Cometriq) and cobimetinib (Cobi). Both use small molecules as the active component. The company has a partnership with Roche to commercialize, market and distribute cobi. Cobi is expected to earn approval in the treatment of melanoma by late 2015, after positive phase-three trial results earlier this week. Cabo is...

2014-06-24 23:02:48

The DrugNews Center is the web’s largest source for prescription drug warnings, research and legal news. Visit http://www.DrugNews.net today. Chicago, IL (PRWEB) June 24, 2014 The birth control safety advocates at DrugNews.net are alerting women who have taken the oral contraceptives Yaz or Yasmin of new litigation news on the site. Recent court records show there are still nearly 9,000 lawsuits pending that allege side effects from the drugs*. DrugNews was created for patients taking...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related